Jeffrey V. Poulton, EVP, Chief Financial Officer at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 796 shares at $242.44 ($192K) on 2025-02-28, disclosed to the SEC on 2025-03-03.
Open-market sale of $192k ALNY by EVP, Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $236.51 | 42 | $10K | 5.2% |
| 2 | $238.33 | 34 | $8K | 4.2% |
| 3 | $239.18 | 35 | $8K | 4.4% |
| 4 | $240.32 | 78 | $19K | 9.7% |
| 5 | $241.51 | 127 | $31K | 15.9% |
| 6 | $242.44 | 300 |
| $73K |
| 37.8% |
| 7 | $243.23 | 121 | $29K | 15.3% |
| 8 | $244.11 | 59 | $14K | 7.5% |
| Total | $241.70 avg | 796 | $192K | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.0M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $3.4M | — | Filing → |